Italy bans Novartis flu vaccines pending tests

ROME/ZURICH Wed Oct 24, 2012 10:45pm IST

A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. REUTERS/Arnd Wiegmann

A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011.

Credit: Reuters/Arnd Wiegmann

Related Topics

Stocks

   
Coal Mining In The Punjab

Coal Mining In The Punjab

In Choa Saidan Shah miners dig coal with crude pick axes and load it onto donkeys to be transported to the surface earning a team of 4 workers around $10 to be split between them.  Slideshow 

ROME/ZURICH (Reuters) - Italy banned the sale and use of anti-influenza vaccines produced by Novartis on Wednesday pending tests for possible side effects, prompting authorities in Switzerland to also take precautionary steps.

The Italian Health Ministry advised citizens not to buy or use the drugs Agrippal, Fluad, subunit Influpozzi and adjunvated Influpozzi until further notice.

It said 487,738 vaccine doses were affected, and the move came after the Italian Pharmaceutical Agency decided further tests on the products may be necessary following indications of possible side effects.

Switzerland's drug watchdog then also raised a precautionary red flag for flu vaccines Agrippal and Fluad, saying that at most 160,000 doses were affected.

"Given the current unclear situation Swissmedic has issued a halt to deliveries for the cited vaccines and recommends not using them until further notice," it said.

Preliminary investigations had shown Italy's ban came after the discovery of white particles in the injections, which could suggest some of the components of the vaccine had clumped together, Swissmedic said.

Novartis said it was cooperating with Italian health authorities to understand the reasons behind the decision, and it had already provided authorities with an assessment in support of the quality, efficacy and safety of the vaccines.

Last week, Italy's Health Ministry said Netherlands-based vaccine maker Crucell, a unit of U.S. drugmaker Johnson & Johnson, had suspended a delivery of 2.36 million seasonal flu vaccine doses to Italy after finding problems with two lots of it.

The ministry said last week it would make up the shortfall by purchasing more doses from other manufacturers.

Italy uses between 10 million and 12 million doses of flu vaccines every year, according to the ministry.

(Reporting By James Mackenzie and Catherine Hornby in Rome, Caroline Copley and Catherine Bosley in Zurich; Editing by Sophie Hares)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Disease Outbreak

REUTERS SHOWCASE

Reading the Brain

Reading the Brain

Guilt may spoil restorative effects of entertainment.  Full Article 

Heart Matters

Heart Matters

Weekday heart attacks still getting quicker treatment at hospitals.  Full Article 

Tackling Stress

Tackling Stress

'Interreality' may enhance stress therapies.  Full Article 

Jogging Helps

Jogging Helps

Short jogs linked to lower risk of death from heart disease.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage